CXCL12 and cholangiocarcinoma: Treatment of cholangiocarcinoma cell lines with PI3K inhibitor (LY294002) or the MEK 1/2 (UO126) attenuated the effect of CXCL12-induced cholangiocarcinoma cell invasion.